New drugs to inhibit growth of breast cancer stem cells!

Breast cancer is one of the most common cancers in the UKOne in seven women is predicted to be affected by the disease throughout their livesthe study at the University of Salford found important clues about how to effectively target mitochondriaMitochondria usually provide all the necessary energy for the proliferation and proliferation of cancer stem cells (CSC's)the medical community generally believes that in many different types of cancer, the growth of cancer stem cells is one of the leading causes of treatment failure, tumor recurrence and cancer spreadCSC with anti-chemotherapy and radiotherapy often causes the tumor to recurThe study, conducted at the University of Salford's Translational Medicine Laboratory, found a candidate drug, Dodecyl-TPP, which can efficiently target mitochondria in CSCsThis approach can reduce the risk of cancer recurrence and spread when treating cancer patientsMichael PLisanti, professor of translational medicine at the University of Salford, said: "Our preclinical studies have identified a new drug candidate for targeted CSC mitochondriaThe study found that Dodecyl-TPP was effective in dying of CSCs hunger, with effective concentrations as low as nanomole levels, blocking their use of oxygen to generate energy in the form of ATPThese findings provide an effective basis for future clinical trials in the fieldScientists at the University of Salford also found five other substances that work in synergy with Dodecyl-TPPThis includes two FDA-approved drugs (strong mycomycin and chloratitis) and two nutritional supplements (vitamin C and flatrix)The study, led by Professor Michael PLisanti and Professor Federica Sotgia, was published in the peer-reviewed journal Frontiers intheThis metabolic approach, which uses a combination of drugs, may improve patient survival by effectively targeting CSCs and preventing tumor recurrence and metastasisAbout 90 percent of cancer patients die from the spread of cancer and the recurrence of tumors, which is the basis for the study of new mitochondrial inhibitorsabout mitochondriamitochondria are "power stations" of cells that drive cell energy production in the form of NAD and ATPStudies have shown that Dodecyl-TPP, as a mitochondrial inhibitor, can cause CSCs to die of hungerATP and NAD are high-energy metabolites necessary for cell survival and reproductionon the Dodecyl-TPPThe TPP consists of a 12-carbon side chain, which is connected to the TPP (tribenzene) sectionTPP acts as a chemical signal that targets the drug to the mitochondriaTPP is more effective at targeting mitochondria in cancer stem cells and cancer cells, but is largely excluded from normal cell mitochondria, reducing its potential toxicity to normal somatic cells: Ernestina Mariana De Francesco et alDodecyl-TPP Targets Mitochondria and Potently FusionS Cancer Stem Cells (CSCs): Synergy FDA-approved Drugs and Natural Compounds (Vitamin C and Berberine), Frontiers in Oncology (2019)DOI: 10.3389/fonc.2019.00615